Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

Rhea-AI Summary

Telix Pharmaceuticals (ASX/NASDAQ: TLX) reported strong H1 2025 financial results, with revenue surging 63% to $390.4 million. The company achieved an Adjusted EBITDA of $21.1 million despite increased operating expenditure from strategic acquisitions and R&D investments.

Key highlights include a group gross profit margin of 53%, R&D investment of $81.6 million (up 47% YoY), and positive operating cash flow of $17.7 million. The Precision Medicine segment saw 30% revenue growth, while RLS Radiopharmacies contributed $109.5 million in revenue. The company maintains its FY 2025 revenue guidance of $770-800 million.

Telix achieved significant pipeline milestones, including completion of Phase 3 enrollment for TLX591 in prostate cancer and regulatory approvals for multiple therapeutic programs.

Positive

• None.

Negative

• Loss before tax of $4.8 million compared to profit of $22.9 million in H1 2024
• Increased finance costs of $18.8 million, including $12.4 million in non-cash costs from convertible bonds
• RLS delivered an Adjusted EBITDA loss of $1.1 million
• Operating profit declined to $10.4 million from $27.7 million in H1 2024

Insights

Pharmaceutical Financial Analyst

Telix delivers 63% revenue growth while strategically investing in pipeline development and manufacturing capabilities for long-term value creation.

Telix's H1 2025 results demonstrate robust commercial momentum with $390.4 million in revenue, a 63% year-over-year increase, putting the company on track to meet its full-year guidance of $770-800 million. The 53% group gross margin reflects a product mix shift incorporating third-party RLS sales, while Illuccix maintains a stable 64% margin.

The adjusted EBITDA of $21.1 million represents a significant decrease from the prior year, primarily due to strategic investments across three key areas. First, Telix has substantially increased R&D spending by 47% to $81.6 million, with over half directed toward their therapeutic pipeline including late-stage radioligand therapy programs. Second, the company has expanded commercial infrastructure to support multiple product launches across regions. Third, substantial investments in manufacturing capabilities through the RLS acquisition and global facility development position Telix to meet future demand.

The company's segmented performance reveals important dynamics. The Precision Medicine segment delivered 30% revenue growth and $104.6 million in adjusted EBITDA, demonstrating the core business strength. Meanwhile, the Manufacturing Solutions segment, particularly the newly acquired RLS radiopharmacies, posted $109.5 million in revenue but an adjusted EBITDA loss as integration continues.

The $4.8 million loss before tax includes $12.4 million in non-cash finance costs from convertible bonds and increased amortization costs following acquisitions. However, Telix maintained positive operating cash flow of $17.7 million, with a healthy cash position of $207.2 million even after $241.8 million in strategic M&A investments.

These results illustrate a company in transition - deploying profits from its established diagnostics business to fund pipeline expansion, geographic growth, and manufacturing capabilities. This strategic reinvestment approach indicates management's focus on building sustainable long-term value beyond current revenue drivers.

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.

H1 2025 key results¹

Group performance²: Reflects strategic investment for long-term value creation

• Revenue of $390.4 million, up by 63%³ and on track to meet full year guidance⁴.
• Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable.
• Adjusted EBITDA⁵ of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and research and development (R&D) investment.
• $81.6 million invested into R&D, a 47% increase year-over-year. Investment was primarily focused on late-stage assets in the therapeutics and precision medicine pipeline. Full year R&D investment guidance is maintained⁶.
• Loss before tax of $4.8 million includes $12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024 and increased amortization cost of $9.5 million (2024 $2.4 million) following RLS acquisition.
• Positive operating net cash flow of $17.7 million, cash balance $207.2 million following $241. 8 million of strategic merger and acquisition (M&A) investment.

Telix Precision Medicine: Commercial business delivers profitable growth

• Precision Medicine segment revenue up by 30% compared to H1 2024, driven by continued increase in Illuccix dose volumes.
• Illuccix gross margin remains stable at 64%.
• Adjusted EBITDA up by 24% year-over-year to $104.6 million.
• Selling and marketing expenses of $40.9 million, reflecting incremental investment in commercial infrastructure for new product launches (Illuccix European launches and Gozellix®, Zircaix® and Pixclara®⁷).

Telix Manufacturing Solutions (TMS): Investment in infrastructure to scale operations and meet future demand

• TMS segment includes RLS Radiopharmacies (RLS, U.S.⁸), IsoTherapeutics (TX, U.S.), and TMS facilities in Sacramento (CA, U.S.), Brussels South (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly augmented global production and manufacturing footprint to support clinical and commercial operations.
  
• Operating expenses of $30.5 million for the segment include $14.9 million for RLS business and $15.6 million to support start-up and integration activities (ex-RLS).
• RLS – the core revenue driver in TMS – reported $109.5 million of revenue, which includes $79.0 million from third-party PET⁹ and SPECT¹⁰ product sales and distribution service fees, and $30.5 million inter-segment revenue.
• RLS delivered an Adjusted EBITDA loss of $1.1 million.
• RLS operating loss includes $6.3 million of depreciation and amortization.

Telix Therapeutics: Reinvesting earnings to accelerate late-stage pipeline

Of the total R&D investment, 54% ($43.9 million) was invested in the therapeutics pipeline. Milestones achieved include:

• TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan): Completed target enrollment of 30 patients for Part 1 of the Phase 3 study in advanced metastatic castration resistant prostate cancer (mCRPC). The trial has received regulatory approval to proceed in Australia, China, Canada, New Zealand, Turkey and Japan.
• TLX592 (²²⁵Ac-PSMA-RADmAb): Approval to commence a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced mCRPC.
• TLX101 (¹³¹I-iodofalan, or 131I-IPA): Approval to commence IPAX BrIGHT, an international pivotal trial, to commence at Australian sites initially.
• TLX090 (¹⁵³Sm-DOTMP): Investigational New Drug (IND) application approved for a Phase 1 bridging study for Telix’s therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone.

Commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the result:

“Telix continues to deliver strong revenue growth while building a foundation for the future. The first half of 2025 was a period of rapid transformation as we expanded our global manufacturing operations, invested in launching new products in new markets, and accelerated the development of our therapeutic pipeline. These investments have positioned Telix for sustainable, long-term growth, while our diversified business provides multiple drivers of success. To generate future revenue growth, we are confident in securing product approvals for Pixclara and Zircaix while advancing geographic and indication expansion for the PSMA portfolio.”

Summary Group financial results

	H1 2025		H1 2024
	US$M		US$M
Revenue	390.4		239.6
Cost of sales	(181.8	)	(82.4	)
Gross profit	208.6		157.2
Research and development (R&D)	(81.6	)	(55.4	)
Selling and marketing	(49.0	)	(24.6	)
Manufacturing and distribution	(18.8	)	(8.4	)
General and administration	(47.7	)	(39.2	)
Other losses (net)	(1.1	)	(1.9	)
Operating profit	10.4		27.7
Finance income	3.6		0.9
Finance costs	(18.8	)	(5.7	)
(Loss)/profit before tax	(4.8	)	22.9
Adjusted EBITDA	21.1		37.1
Cash from operating activities	17.7		23.3

Guidance

• Telix confirms FY 2025 revenue guidance of US$770 million to US$800 million¹¹.
• Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS¹².
• Telix confirms R&D expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024.
  

lnvestor call

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).

Participants can register for the webcast by clicking here: https://edge.media-server.com/mmc/p/x4gytx8w/ or the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Ms. Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context
of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

1. See summary Group financial results table at end of this document.
2. Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).
3. All comparisons to H1 2024 results.
4. FY 2025 revenue guidance of US$770 million to US$800 million.
5. Earnings before interest, tax, depreciation and amortization.
6. Increased investment range for FY 2025 expected to be 20% to 25% compared to FY 2024.
7. Launch and brand names subject to final regulatory approval.
8. RLS network is comprised of 28 locations across the U.S.
9. Positron emission tomography.
10. Single photon emission computed tomography.
11. Refer to ASX disclosures 20 February 2025.
12. See Guidance Disclaimer for further information.

FAQ

What was Telix Pharmaceuticals' (TLX) revenue growth in H1 2025?

Telix reported revenue of $390.4 million in H1 2025, representing a 63% increase compared to H1 2024.

How much did Telix (TLX) invest in R&D during H1 2025?

Telix invested $81.6 million in R&D during H1 2025, a 47% increase year-over-year, primarily focused on late-stage assets in therapeutics and precision medicine.

What is Telix's (TLX) revenue guidance for FY 2025?

Telix confirmed its FY 2025 revenue guidance of $770 million to $800 million, which includes Illuccix sales and 11 months of revenue contribution from RLS.

How did Telix's Precision Medicine segment perform in H1 2025?

The Precision Medicine segment revenue grew 30% compared to H1 2024, with Illuccix maintaining a stable gross margin of 64% and achieving an Adjusted EBITDA of $104.6 million, up 24% year-over-year.

What were the key clinical milestones achieved by Telix (TLX) in H1 2025?

Telix completed target enrollment for Phase 3 TLX591 study in prostate cancer, received approval for TLX592 first-in-human study, gained approval for IPAX BrIGHT trial with TLX101, and received IND approval for TLX090 Phase 1 study.

What was Telix's (TLX) cash position at the end of H1 2025?

Telix maintained a cash balance of $207.2 million after investing $241.8 million in strategic mergers and acquisitions, with positive operating cash flow of $17.7 million.